Fruquintinib

Gastric Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors for the disease.

Fruquintinib plus paclitaxel significantly improved PFS in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to results from a phase 3 trial presented during an ASCO Plenary Series session.

The FDA approved fruquintinib for certain adults with previously treated metastatic colorectal cancer.

Treatment with fruquintinib resulted in a significant and clinically meaningful survival benefit when compared with placebo among patients with refractory metastatic colorectal cancer, according to data published in The Lancet.